Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 888

Sort by

Sort Order Select

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Luke Mountjoy, DO, Daniel Almquist, MD, Henry Ofori, Pharm D, RPh, Marlene Girardo, MS, Margaret McCallen, Pharm D, RPh

Blood (2019) 134 (Supplement_1): 3262.

https://doi.org/10.1182/blood-2019-128644

Published: 2019

Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Blood (2019) 134 (Supplement_1): 3116.

https://doi.org/10.1182/blood-2019-123205

Published: 2019

Journal Articles

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roni Shouval, Adi Eshel, MSc, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, MD, Shalev Fried, Mika Geva, MD, Elizaveta Kouniavsky, Amir A Kuperman, MD MSc, Yoram Louzoun, PhD, Omry Koren, PhD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3265.

https://doi.org/10.1182/blood-2019-125433

Published: 2019

Journal Articles

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Alessandra Cupri, MD, Salvatore Leotta, MD, Uros Markovic, MD, Maria Grazia Camuglia, PhD, Giulio Antonio Milone, MD, Angelo Curto Pelle, MD, Valerio Leotta, MD, Mary Ann Di Giorgio, MD, Anna Bulla, MD, Di Marco Anna Lia, PhD, Gaetano Moschetti, MD, Giuseppe Milone, MD PhD

Blood (2019) 134 (Supplement_1): 3271.

https://doi.org/10.1182/blood-2019-127120

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Journal Articles

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Luibov Tsvetkova, Tatiana A Bykova, MD PhD, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Marina O Popova, MD PhD, Elena Vladimirovna Semenova, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 4510.

https://doi.org/10.1182/blood-2019-128155

Published: 2019

Journal Articles

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

Monica Magdalena Rivera Franco, MDMSc, Eucario Leon Rodriguez, MD

Blood (2019) 134 (Supplement_1): 4480.

https://doi.org/10.1182/blood-2019-122203

Published: 2019

Journal Articles

The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation

Lily Blair, PhD, Jonathan U. Peled, MD, Paul A Giardina, John B. Slingerland, BSc, Ann E. Slingerland, BSc, Desiree Hollemon, MPH, MSN, Carine Ho, Sivan Bercovici, Asim Ahmed, David K Hong, MD, Sergio A. Giralt, MD, Ying Taur, MD MPH, Marcel R.M. van den Brink, MD PhD, Kate A Markey, PhDMBBS,FRACP

Blood (2019) 134 (Supplement_1): 4513.

https://doi.org/10.1182/blood-2019-129272

Published: 2019

Journal Articles

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Lidia Gil, MD PhD, Robert C. Shepard, MD, Sandra L Silberman, MD PhD, Ewa Maria Zak, MSc, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5147.

https://doi.org/10.1182/blood-2019-129268

Published: 2019

Journal Articles

Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia

Ashley Siryk, PharmD, Haley Grunwald, PharmD, Amanda Brahim, PharmD, Frank Gentile, PharmD, Faina Shenderov, PharmD, Carmen Ballestas, MD

Blood (2019) 134 (Supplement_1): 5074.

https://doi.org/10.1182/blood-2019-130268

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only